Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback